SAN DIEGO, and BRUSSELS, Belgium, May 12 /PRNewswire-FirstCall/ -- Volcano Corporation , a leading manufacturer and developer of intravascular ultrasound (IVUS), functional measurement (FM) and Optical Coherence Tomography (OCT) products designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, announced today the 1,000th worldwide placement of the newest s5 and s5i integrated imaging consoles since the formal launch in April of 2006. This announcement comes just prior to Volcano’s participation in the EuroPCR 2008 Congress, to be held in Barcelona, Spain, from May 12-15th. During the PCR, Volcano will highlight the s5i integrated Imaging System, complete with two new functionality options, which enable high frequency rotational IVUS and FFR to operate on the same platform as Volcano’s phased array IVUS catheters.
Scott Huennekens, President and Chief Executive Officer of Volcano, commented, “Reaching this milestone as quickly as we have is a clear indication of the clinical adoption of IVUS and FFR, and the competitiveness of our product. More and more physicians are using intravascular imaging to measure lesion significance and improve PCI technique. The ease of use and flexibility of our newest systems have been very well received. These new systems are gaining traction with both new IVUS users, as well as those who are looking to replace their legacy IVUS technology.”
The newest Volcano s5i integrated system now available for evaluation is the only imaging system that accommodates phased array IVUS, high frequency rotational IVUS, and integrated FFR lesion severity assessment. Mr. Huennekens continued, “By adding high resolution rotational IVUS and pressure-based FFR to our phased array s5 imaging platform, we provide a level of technology, clinical utility and convenience that is un-matched in the intravascular imaging field. No other company provides a system that integrates this level of functionality and convenience in a single platform. Our message now is simple: Volcano offers physicians all three technologies on one system -- you can choose which technology is best for your patient and clinical team.”
Earlier generation consoles included only one of the three technologies now available on the s5i. If a hospital wanted to equip a new lab with all three technologies, they would have to acquire three separate consoles, each with a different measurement modality, training requirements and data storage protocols. The Volcano s5i can now accommodate three primary intravascular diagnostic tools in regular use by cardiologists today (high frequency rotational IVUS, fast and simple phased array IVUS, and pressure-based FFR guidewires) on a single platform, making Volcano’s s5 and s5i imaging systems more flexible than ever before.
Presence at EuroPCR08
Volcano’s presence at the EuroPCR 2008 Congress in Barcelona will include live case transmissions with IVUS, FFR, and OCT, scientific symposia sponsorship, first-in-man clinical experience and live product demonstrations at Volcano booth #B02. Volcano will also participate in the following scientific symposia during the program.
About Volcano Corporation
Volcano Corporation offers a broad suite of devices designed to facilitate endovascular procedures, enhance the diagnosis of vascular and structural heart diseases and guide optimal therapies. The company’s intravascular ultrasound (IVUS) product line includes ultrasound consoles that can be integrated directly into virtually any modern cath lab. Volcano IVUS offers unique features, including both single-use phased array and rotational IVUS imaging catheters, and advanced functionality options such as VH(TM) tissue characterization and ChromaFlo(R). Internal DICOM networking provided by DICOM by Merge. Volcano also provides functional measurement (FM) consoles and single-use pressure and flow guide wires and is developing a line of ultra high-resolution Optical Coherence Tomography systems and catheters. Currently, more than 3,200 Volcano IVUS and FM systems are installed worldwide, with approximately half of its revenues coming from outside the United States. For more information, visit the company’s website at http://www.volcanocorp.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release regarding Volcano’s business that are not historical facts may be considered “forward-looking statements,” including statements regarding the company’s success and timing of product development and new product introductions, including the installations of the Volcano imaging systems, the expected performance of its products and product enhancements, the integration of our products into new or existing cath labs, and market penetration, conditions and expectations. Forward-looking statements are based on management’s current, preliminary expectations and are subject to risks and uncertainties, which may cause Volcano’s results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from the results predicted are detailed in the company’s annual report on Form 10-K, quarterly report on Form 10-Q, and other filings made with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Volcano undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.
CONTACT: Sandra Mercer, Associate Director of Marketing Communications of
Volcano Corporation, +1-916-952-2133, smercer@volcanocorp.com; or Shalon
Roth of Ricochet Public Relations, +1-212-679-3300, ext. 127,
sroth@ricochetpr.com, for Volcano Corporation
Web site: http://www.volcanocorp.com/
